Stockholders' Equity Attributable to Parent of TG THERAPEUTICS, INC. from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
TG THERAPEUTICS, INC. quarterly Stockholders' Equity Attributable to Parent in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
  • TG THERAPEUTICS, INC. Stockholders' Equity Attributable to Parent for the quarter ending 31 Dec 2025 was $648,020,000, a 191% increase year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

TG THERAPEUTICS, INC. Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $648,020,000 +$425,656,000 +191% 31 Dec 2025 10-K 27 Feb 2026 2025 FY
Q3 2025 $607,218,000 +$415,061,000 +216% 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $276,432,000 +$98,864,000 +56% 30 Jun 2025 10-Q 05 Nov 2025 2025 Q3
Q1 2025 $237,289,000 +$77,180,000 +48% 31 Mar 2025 10-Q 05 Nov 2025 2025 Q3
Q4 2024 $222,364,000 +$61,862,000 +39% 31 Dec 2024 10-K 27 Feb 2026 2025 FY
Q3 2024 $192,157,000 +$27,388,000 +17% 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $177,568,000 +$137,115,000 +339% 30 Jun 2024 10-Q 05 Nov 2025 2025 Q3
Q1 2024 $160,109,000 +$132,676,000 +484% 31 Mar 2024 10-Q 05 Nov 2025 2025 Q3
Q4 2023 $160,502,000 +$101,915,000 +174% 31 Dec 2023 10-K 27 Feb 2026 2025 FY
Q3 2023 $164,769,000 +$64,288,000 +64% 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $40,453,000 -$88,582,000 -69% 30 Jun 2023 10-Q 07 Nov 2024 2024 Q3
Q1 2023 $27,433,000 -$142,953,000 -84% 31 Mar 2023 10-Q 07 Nov 2024 2024 Q3
Q4 2022 $58,587,000 -$178,566,000 -75% 31 Dec 2022 10-K 27 Feb 2026 2025 FY
Q3 2022 $100,481,000 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $129,035,000 30 Jun 2022 10-Q 06 Nov 2023 2023 Q3
Q1 2022 $170,386,000 31 Mar 2022 10-Q 06 Nov 2023 2023 Q3
Q4 2021 $237,153,000 -$282,197,000 -54% 31 Dec 2021 10-K 03 Mar 2025 2024 FY
Q4 2020 $519,350,000 31 Dec 2020 10-K 29 Feb 2024 2023 FY
Q4 2012 $15,550,301 +$5,925,780 +62% 31 Dec 2012 10-K 21 Mar 2013 2012 FY
Q3 2012 $9,371,535 +$9,666,153 30 Sep 2012 10-Q 14 Nov 2012 2012 Q3
Q2 2012 $11,015,683 +$13,165,230 30 Jun 2012 10-Q/A 07 Sep 2012 2012 Q2
Q1 2012 $11,738,346 31 Mar 2012 10-Q 14 May 2012 2012 Q1
Q4 2011 $9,624,521 +$14,988,822 31 Dec 2011 10-K 21 Mar 2013 2012 FY
Q3 2011 $294,618 30 Sep 2011 10-Q 14 Nov 2011 2011 Q3
Q2 2011 $2,149,547 30 Jun 2011 10-Q/A 14 Sep 2011 2011 Q2
Q4 2010 $5,364,301 31 Dec 2010 10-Q 14 Nov 2011 2011 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.